-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-08
ONC:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 209.41Change
-11.13 (-5.05)%Market Cap
USD 28.70BVolume
0.61MVerdict
Verdict
Values as of: 2025-04-08
COMMON STOCK | Biotechnology |
Last Closing
USD 209.41Change
-11.13 (-5.05)%Market Cap
USD 28.70BVolume
0.61MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
-14.60 (-2.92%) |
USD 126.52B |
REGN | Regeneron Pharmaceuticals Inc |
-8.63 (-1.55%) |
USD 69.68B |
ARGX | argenx NV ADR |
-17.79 (-2.94%) |
USD 35.43B |
ALNY | Alnylam Pharmaceuticals Inc |
-0.43 (-0.19%) |
USD 30.51B |
RPRX | Royalty Pharma Plc |
-0.26 (-0.80%) |
USD 19.31B |
SMMT | Summit Therapeutics PLC |
-1.57 (-6.38%) |
USD 14.57B |
INSM | Insmed Inc |
-0.87 (-1.22%) |
USD 12.52B |
INCY | Incyte Corporation |
-0.73 (-1.25%) |
USD 11.72B |
BMRN | Biomarin Pharmaceutical Inc |
-1.20 (-2.00%) |
USD 11.50B |
MRNA | Moderna Inc |
-1.05 (-4.00%) |
USD 9.91B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
L6EW:LSE | Ossiam Stoxx Europe 600 E.. | 6.12 % | 0.00 % |
+38.00 (+-0.21%) |
USD 0.11B |
S6EW:SW | Ossiam STOXX® Europe 600.. | 6.12 % | 0.00 % |
N/A |
USD 0.11B |
XS3R:LSE | Xtrackers MSCI Europe Con.. | 2.88 % | 0.00 % |
+150.00 (+-0.21%) |
USD 0.05B |
EDGE:CA | Evolve Innovation Index F.. | 1.96 % | 0.60 % |
-0.91 (-0.21%) |
CAD 0.04B |
EDGE-U:CA | Evolve Innovation Index F.. | 1.84 % | 0.00 % |
-0.04 (-0.21%) |
N/A |
S6EW:PA | Ossiam Stoxx Europe 600 E.. | 0.00 % | 0.00 % |
-0.30 (-0.21%) |
USD 0.11B |
ETLI:XETRA | L&G Pharma Breakthrough U.. | 0.00 % | 0.00 % |
-0.08 (-0.21%) |
USD 0.02B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | N/A | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | N/A | N/A | N/A | N/A | N/A | ||
Market Capitalization | 28.70B | 99% | N/A | 97% | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector